Dr. Mark Geyer, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
4 reported clinical trials
11 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD371 positive
Stage IV
IDH positive
2Acute Lymphoblastic Leukemia
CD19 positive
BCR-ABL1 positive
Philadelphia chromosome negative
Affiliated Hospitals
Clinical Trials Mark Geyer, MD is currently running
CAR T Cell Therapy
for Acute Myeloid Leukemia
This trial is testing the safety of using specially modified immune cells to treat cancer patients who haven't responded to other treatments. The goal is to find the highest dose that causes few or mild side effects.
Recruiting1 award Phase 141 criteria
Radioimmunotherapy + CAR T-cell Therapy
for Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.
Recruiting1 award Phase < 126 criteria
More about Mark Geyer, MD
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mark Geyer, MD has experience with
- CD371-YSNVZ-IL18 CAR T Cells
- Blinatumomab
- Dasatinib
- 19-28z T CELLS
- Autologous Stem Cell Transplantation
- Carmustine
Breakdown of trials Mark Geyer, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Lymphoblastic Leukemia
Cancer
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Geyer, MD specialize in?
Mark Geyer, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD371 positive patients, or patients who are Stage IV.
Is Mark Geyer, MD currently recruiting for clinical trials?
Yes, Mark Geyer, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Mark Geyer, MD has studied deeply?
Yes, Mark Geyer, MD has studied treatments such as CD371-YSNVZ-IL18 CAR T cells, Blinatumomab, Dasatinib.
What is the best way to schedule an appointment with Mark Geyer, MD?
Apply for one of the trials that Mark Geyer, MD is conducting.
What is the office address of Mark Geyer, MD?
The office of Mark Geyer, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.